USPTO serial 79313038
HAEMATOKINE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 23, 2022
- Examiner
- STADELI, MARTA ANN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HAEMATOKINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark E. Olds
Mark E. Olds Muncy, Geissler, Olds & Lowe, P.C.4000 Legato Road Suite 310Fairfax, VA 22033UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry, science and photography, as well as in agriculture, horticulture and forestry, except fungicides, herbicides, insecticides and parasiticides; Biological preparations for use in industry and science; Media for cell culture for use in the biotechnological industry, namely, cell culture media for scientific and research use; Media for cell culture for use in non-medical research laboratories, namely, cell culture media for laboratory use; Biological preparation for use in cell cultures other than for medical or veterinary use; Culture media for microbiology, for scientific and research use; Cell growth media for growing cells for scientific use; Biological preparation for use in cell cultures, other than for medical or veterinary use; Cultures of cell media other than for medical or veterinary use, namely culture media for scientific and research use; Cultures of microorganisms, other than for medical and veterinary use; Blood culture media being cell culture media for scientific use; Biological preparations for use in cell cultures, other than for medical or veterinary purposes; Stem cells, other than for medical or veterinary purposes; Stem cells for scientific purposes; Stem cells for research purposes | ACTIVE | — |
| 005 | Pharmaceuticals, medical and veterinary preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Sanitary preparations for medical purposes; Stem cells for medical or veterinary use; Stem cells for medical purposes; Tumor suppressing agents; Pharmaceutical preparations, namely, antineoplastics; Anti-neoplastic preparations of chemical origin, namely, pharmaceutical preparations for hematological malignancies, bone marrow dysfunction or suppressions; Anti-neoplastic preparations of microbial origin, namely, pharmaceutical preparations for hematological malignancies, bone marrow dysfunction or suppressions; Anti-cancer preparations; Compounds for treating cancer, namely, anti-cancer preparations; Antibodies for medical purposes for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Antibodies for medical use to treat inflammation and cancer growth and spread; Adjuvants for medical purposes; Vaccine adjuvants; Biological adjuvants for medical purposes; Anti-inflammatories; Antigens, namely, tumour antigens for medical diagnostic purposes; Biological preparations for the treatment of cancer; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical use, namely, biological preparations for the treatment of conditions associated with poor production of hematopoietic stem cells; Culture media for medical use, namely, culture media for use in augmentation of blood cells, bone marrow and tissues for medical purposes; Media for bacteriological cultures; Cell growth media for growing cells for medical use; Biological preparations for medical purposes, namely, biological preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Mixed biological preparations for medical purposes, namely, mixed biological preparations for the prevention and treatment of infectious diseases; Biological preparations for veterinary purposes, namely, biological preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations, namely, immunomodulators; Immunostimulants; Injectable pharmaceuticals for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for treating malignant tumors; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the prevention of tumours; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances with anti-inflammatory properties for treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of autoimmune disorders; Pharmaceutical preparations for use in hematology; Pharmaceutical preparations for the prevention of diseases of the immune system; Pharmaceutical preparations for the prevention of disorders of the immune system; Pharmaceutical preparations for the prevention of autoimmune diseases; Pharmaceutical preparations for the treatment of disorders caused by bacteria; Pharmaceutical preparations for the treatment of diseases caused by bacteria; Pharmaceutical preparations for the prevention of disorders of the respiratory system; Pharmaceutical preparations for the prevention of inflammatory disorders; Pharmaceutical preparations for the prevention of autoimmune disorders; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in tissue transplantation; Pharmaceutical products for the treatment of bone diseases; Regulatory proteins for medical use, namely, protein arrays for medical diagnosis purposes; Serotherapeutic medicines, namely, pharmaceutical preparations for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Synthetic peptides for pharmaceutical purposes for the treatment of hematological malignancies, bone marrow dysfunction or suppressions; Pharmaceutical products for treating respiratory diseases; Pharmaceutical compounds for treating respiratory diseases; Pharmaceutical preparations for treating respiratory diseases; Pharmaceutical compounds for treating correlated pulmonary syndromes; Pharmaceutical preparations for treatment and prevention of ischemic conditions, inflammation and organ damages resulting from tissue traumas, reperfusion injuries, cancer, cancer metastasis, inflammatory conditions and allergic conditions; Pharmaceutical preparations for treatment and prevention of multi-organ failure, acute lung injury and acute respiratory distress syndrome in adults, adolescents, children, infants and neonates | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Faron Pharmaceuticals Oy
- Other trademarks owned by Faron Pharmaceuticals Oy
- Other trademarks owned by Faron Pharmaceuticals Oy
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named HAEMATOKINE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 26, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 28, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 1, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 1, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 23, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 23, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 23, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 7, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 7, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 18, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 29, 2022 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Apr 16, 2022 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Apr 1, 2022 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Mar 30, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 30, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 30, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 30, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 30, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 25, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 25, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 25, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 18, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 18, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 18, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 18, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 18, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 18, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 25, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 27, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 27, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 9, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 8, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 30, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 16, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 12, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 10, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |